Effect of Anagliptin on Vascular Injury in the Femoral Artery of Type 2 Diabetic Rats.

Otsuka Long-Evans Tokushima Fatty advanced glycation end-product diabetes mellitus

Journal

Biological & pharmaceutical bulletin
ISSN: 1347-5215
Titre abrégé: Biol Pharm Bull
Pays: Japan
ID NLM: 9311984

Informations de publication

Date de publication:
2024
Historique:
medline: 22 1 2024
pubmed: 22 1 2024
entrez: 21 1 2024
Statut: ppublish

Résumé

Patients with diabetes mellitus (DM) often experience complications such as peripheral arterial disease (PAD), which is thought to be caused by vascular damage resulting from increased oxidative stress. Dipeptidyl peptidase-4 inhibitors have been reported to reduce oxidative stress, although the exact mechanism remains unclear. This study aimed to investigate the impact of long-term (6 weeks) anagliptin treatment at a dose of 200 mg/kg/d against oxidative stress in the femoral artery of Otsuka Long-Evans Tokushima Fatty (OLETF) rats using a well-established animal model for type 2 DM. Serum toxic advanced glycation end-products concentrations and blood glucose levels after glucose loading were significantly elevated in OLETF rats compared to Long-Evans Tokushima Otsuka (LETO) rats but were significantly suppressed by anagliptin administration. Plasma glucagon-like peptide-1 concentrations after glucose loading were significantly increased in anagliptin-treated rats. Superoxide production and reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity in femoral arteries were significantly increased in OLETF rats compared to LETO rats but were significantly decreased by anagliptin administration. The expressions of NADPH oxidase components (p22

Identifiants

pubmed: 38246646
doi: 10.1248/bpb.b23-00706
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

204-212

Auteurs

Masato Noda (M)

Department of Clinical Pharmacy, Graduate School of Pharmaceutical Sciences, Nagoya City University.

Chigusa Kikuchi (C)

Department of Clinical Pharmacy, Graduate School of Pharmaceutical Sciences, Nagoya City University.
Laboratory of Community Medicine, Showa Pharmaceutical University.
Educational Research Center for Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Nagoya City University.

Eisei Hori (E)

Department of Clinical Pharmacy, Graduate School of Pharmaceutical Sciences, Nagoya City University.
Educational Research Center for Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Nagoya City University.

Takahiro Iwao (T)

Department of Clinical Pharmacy, Graduate School of Pharmaceutical Sciences, Nagoya City University.
Educational Research Center for Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Nagoya City University.

Chie Nagami (C)

Educational Research Center for Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Nagoya City University.

Masayoshi Takeuchi (M)

Department of Advanced Medicine, Medical Research Institute, Kanazawa Medical University.

Tamihide Matsunaga (T)

Department of Clinical Pharmacy, Graduate School of Pharmaceutical Sciences, Nagoya City University.
Educational Research Center for Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Nagoya City University.

Classifications MeSH